VERU INC (VERU)
US92536C1036 - Common Stock
VERU Stock Earnings: Veru Misses EPS, Beats Revenue for Q2 2024
VERU stock results show that Veru missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles...
Veru to Present at the GLP-1 Based Therapeutics Summit
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative...
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative...
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter...
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative...
Veru Reschedules Annual Meeting of Shareholders
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial...
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative...
Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q (NASDAQ:VERU)
Veru, a biopharmaceutical company, has received a delinquency notification letter from Nasdaq due to non-compliance with filing requirements.
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative...
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative...
The 3 Best Penny Stocks to Buy in February 2024
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
Veru Reports Fiscal 2024 First Quarter Financial Highlights
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has...
Veru eyes better weight loss drugs as FDA clears trial
Veru (VERU) receives FDA clearance to begin a mid-stage trial of enobosarm, an oral therapy designed to improve the effects of weight loss drugs. Read more here.
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss...
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel...
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel...
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel...
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel...
VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Veru stock falls after it prices its public offering at $0.72 per share (NASDAQ:VERU)
Shares of Veru (VERU) drop 8.10% in pre-market trading as the company announces a public offering of 45.83M shares at $0.72 per share, aiming to raise...
Veru Announces Pricing of Public Offering of Common Stock
MIAMI, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines...
Veru Announces Proposed Public Offering of Common Stock
MIAMI, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines...
Monday Sector Laggards: Drugs, Biotechnology Stocks
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU). Such investors are advised...
Veru to conduct Phase2b study with enobosarm, GLP-1 weight-loss drugs (NASDAQ:VERU)
Veru is planning to conduct a Phase 2b study to evaluate enobosarm's potential in reducing muscle loss and increasing fat loss in patients using GLP-1 drugs for weight loss.
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further
-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to...
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any...